According to the report, in 2018 North America held a considerable share in the market. North America is expected to witness promising growth during the forecast period 2019-2026. Increasing approvals in the region for immunology biosimilars product development is likely to contribute towards market growth.
Browse Complete Report Details @
Increasing cases of tumor or diseases such as arthritis and others are expected to propel growth in the global immunology biosimilars market. Fortune Business Insights studies the market in detail in a report, titled “Immunology Biosimilars Market Size, Share and Global Trend By Disease (Inflammatory Bowel Disease, Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography Forecast till 2026.”
Asia Pacific is anticipated to expand at a faster CAGR. Japan offers a lot of opportunity for immunology biosimilars. Owing to receiving the approval of eight biosimilars in Japan since 2016, the market is foreseen to witness growth. Furthermore, high usage of biosimilars in other application such as rheumatoid arthritis is expected to encourage the adoption of biosimilar drugs.
Request Sample PDF [email protected]
Some of the Main Key Players Covered in the Report:
- Mylan N.V.
- STADA MENA
- Celltrion Healthcare Co.,Ltd.
- KBI Biopharma
Increasing Healthcare Expenditure to Drive the Market
Cheaper pricing of biosimilar drugs compared to biologics and increasing healthcare expenditure are some factors expected to drive the market. Moreover, expiry of patents of some biologics such as Humira, Enbrel, and others is likely to fuel the demand for biosimilar drugs.
The complex manufacturing process of biosimilars and stringent regulations for approval of biosimilar products are some key factors that may restrain the market. Moreover, the slow adoption of a biosimilar in developing nations is hampering the growth rate in the market.
The market is Witnessing Frequent Product Launch
The immunology biosimilar of UDENYCA (pegfilgrastim-CQB) received approval from the Food and Drug Administration in 2018. The product was developed by Coherus Biosciences and KBI Biopharma, Inc. and its reference product is Neulasta. Certain development is expected to contribute towards faster adoption of biosimilars.
Some players have adopted innovative strategies such as mergers and acquisitions to succeed in the market. Besides this, the Food and Drug Administration announced the approval for Celltrion and Teva’s rituximab biosimilar called Proximain 2018. This is a kind of immunotherapy and has indications of treating cancer. Some of the key players operating in the global immunology biosimilars market are Novartis AG, Pfizer Inc., Mylan N.V., AbbVie Inc., STADA Arzneimittel AG, Celltrion, Inc., KBI Biopharma, Inc., and Amgen Inc.
More Trending Topics from Future Business Insights:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.